Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on September 25, 2025, by Enlivex Therapeutics Ltd., a foreign private issuer organized under Israeli law, announces the scheduling of its Annual General Meeting of Shareholders. The filing serves as a notification to shareholders and the SEC regarding upcoming corporate governance activities.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly informational regarding the Annual Meeting and does not contain financial statements or performance data.
Material Changes
No material changes to financial position or operations are reported in this document. The primary update is the confirmation of the Annual Meeting date and location.
Guidance, Outlook, and Management Commentary
Management has announced that the Annual General Meeting will be held on Monday, November 10, 2025, at 7:00 p.m. Israel time. The meeting will take place at the company's principal executive offices located at 14 Einstein Street, Nes Ziona, Israel. The filing incorporates the Notice and Proxy Statement (Exhibit 99.1) and the Proxy Card (Exhibit 99.2) by reference, which contain details on matters to be voted upon.
Key Facts for Investor Verification
- Meeting Date: November 10, 2025.
- Meeting Time: 7:00 p.m. Israel time.
- Location: 14 Einstein Street, Nes Ziona, Israel 7403618.
- Documentation: Review attached Exhibit 99.1 (Notice and Proxy Statement) for specific agenda items and voting instructions.
- Financial Data: No financial metrics are included in this specific filing; refer to the most recent Form 20-F or quarterly reports for financial performance.